Sustained use of GLP-1 medications is associated with slower medical cost growth over time, according to new findings from Aon. The analysis examined claims data from more than 190,000 GLP-1 users between 2022 and 2025 and found that consistent use—particularly with high adherence—was linked to lower medical cost growth compared to non-users.
The research suggests cost trends improve the longer patients remain on therapy, with the strongest impact seen among individuals using GLP-1s for diabetes and those with high adherence rates. Female GLP-1 users also experienced notable reductions in hospitalizations for cardiovascular events and certain cancer diagnoses, though some increased risks, such as gallbladder surgery, were observed.
While total costs for GLP-1 users remain higher due to drug expenses, Aon notes that future pricing pressures and new formulations could help narrow the gap. The findings highlight the importance of long-term adherence strategies and data-driven benefit design as employers evaluate GLP-1 coverage decisions.